@article{TCR16942,
author = {Richard E. Kast},
title = {Postoperative capecitabine in breast cancer neoadjuvant failures},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 9},
year = {2017},
keywords = {},
abstract = {In the 1 June 2017 issue of New England Journal of Medicine, Masuda et al. presented important new findings on capecitabine in HER2-negative breast cancer (1). All patients received standard neoadjuvant chemotherapy treatment before surgery with an anthracycline or a taxane, or both. Masuda et al. gave oral capecitabine, 1,250 mg/m2
twice daily on days 1 to 14, nothing days 15 to 21, for 6 to 8 cycles after surgical resection to those whose surgical tissue showed residual invasive breast cancer.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/16942}
}